Healthcare Equipment and Supplies
Company Overview of Immucor, Inc.
Immucor Inc. and its subsidiaries develop, manufacture, and sell reagents and automated systems used primarily by hospitals, clinical labs, and blood banks in tests to detect and identify certain properties of the cell and serum components of human blood before blood transfusions. The company’s reagent product lines include abo blood grouping and Rh blood typing reagents, anti-human globulin serums, reagent red blood cells, rare serums, antibody potentiators, quality control systems, monoclonal antibody-based reagents, technical proficiency systems, and a fetal bleed screen kit, as well as Capture-P, Capture-R, Capture-CMV, Capture-S, and Capture-R Select reagents. These are used in tests to...
3130 Gateway Drive
PO Box 5625
Norcross, GA 30091
Founded in 1982
Key Executives for Immucor, Inc.
Chairman of the Board, Chief Executive Officer and President
Chief Financial Officer, Chief Accounting Officer, Vice President and Vice President of International Transfusion Diagnostics
Vice President of Operations
Vice President of International Finance
Compensation as of Fiscal Year 2015.
Immucor, Inc. Key Developments
Immucor, Inc. Announces FDA Clearance for the Latest Release of ImmuLINK® (V1.7)
Mar 21 16
Immucor, Inc. announced FDA clearance for the latest release of ImmuLINK® (v1.7), the company’s centralized data management solution that supports greater testing efficiency and safety within transfusion medicine. The latest release of ImmuLINK includes a molecular module that helps users manage the workflow associated with running Immucor’s PreciseType HEA test, reducing manual data entry and significantly increasing the number of tests a lab may perform and report. The PreciseType HEA test is the first and only FDA-approved molecular typing solution and is eligible for reimbursement across the U.S. ImmuLINK v1.7 enhancements, specifically tailored to PreciseType HEA users, include: Antigen transfer interface to eliminate manual entry of antigen results into a laboratory information system (LIS); Barcode capability to assist with sample tracking during DNA extraction on the QIAcube; and a Molecular driver to help users set up PreciseType HEA. Additionally, ImmuLINK v1.7 now aggregates all serology and molecular IVD test results from the Echo®, NEO® and PreciseType platforms. ImmuLINK v1.7 generates a single report with a complete donor or patient testing history.
Immucor Presents at J.P. Morgan Global High Yield & Leveraged Finance Conference, Mar-01-2016 09:40 AM
Feb 12 16
Immucor Presents at J.P. Morgan Global High Yield & Leveraged Finance Conference, Mar-01-2016 09:40 AM. Venue: Loews Miami Beach Hotel, Miami Beach, Florida, United States. Speakers: Jeffrey Binder, President & CEO.
Immucor, Inc. Reports Cash Flow Results for the Second Quarter of Fiscal 2016
Feb 2 16
Immucor, Inc. reported cash flow results for the second quarter of fiscal 2016. For the quarter, the company reported net cash provided by operating activities was $15.9 million in the current quarter and $15.3 million for the prior quarter.
Similar Private Companies By Industry
Recent Private Companies Transactions